Is Cell-free fetal DNA testing a safe option for women in a high-risk population after combined first-trimester testing?

Date publication

janvier 2022

Journal

Journal of gynecology obstetrics and human reproduction

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BONNET Céline

Tous les auteurs :
Dap M, Caffin L, Perdriolle-Galet E, Bonnet C, Morel O

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35114410

Résumé

Our study aimed to examine the relevance of cell-free fetal DNA (cfDNA) testing on the screening of chromosomal defects and the issue of pregnancies in patients with a risk over 1:50 after the first-trimester combined test.

Mots clés

cell-free fetal DNA, combined first trimester screening, high risk, non-invasive prenatal testing, trisomy 21

Référence

J Gynecol Obstet Hum Reprod. 2022 Jan 31;:102329